Search Results
Sep 07, 2026, 15:03 ET Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders.
More news about: Halper Sadeh LLP
Aug 31, 2026, 22:51 ET Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
More news about: THE ROSEN LAW FIRM, P. A.
Aug 31, 2026, 16:05 ET TransMedics to Present at Upcoming September Investor Conferences
ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Aug 28, 2026, 22:00 ET TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TransMedics Group, Inc. (NasdaqGM: TMDX) ("TransMedics" or the "Company").
More news about: Kahn Swick & Foti, LLC
Aug 25, 2026, 08:00 ET Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders.
More news about: Halper Sadeh LLP
Aug 21, 2026, 07:45 ET Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
More news about: THE ROSEN LAW FIRM, P. A.
Aug 18, 2026, 09:55 ET Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
More news about: THE ROSEN LAW FIRM, P. A.
Aug 17, 2026, 03:00 ET Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders.
More news about: Halper Sadeh LLP
Aug 11, 2026, 17:50 ET Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
More news about: THE ROSEN LAW FIRM, P. A.
Aug 05, 2026, 18:35 ET TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).
More news about: THE ROSEN LAW FIRM, P. A.
Aug 04, 2026, 16:05 ET TransMedics Reports Second Quarter 2026 Financial Results
ANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported
More news about: TransMedics Group, Inc.
Aug 03, 2026, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Jul 28, 2026, 16:29 ET TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
ANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Jul 24, 2026, 14:25 ET Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders.
More news about: Halper Sadeh LLP
Jul 21, 2026, 16:05 ET TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
ANDOVER, Mass., July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced
More news about: TransMedics Group, Inc.
Jul 06, 2026, 07:05 ET TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
ANDOVER, Mass., July 6, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
May 21, 2026, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
May 19, 2026, 16:05 ET TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
May 05, 2026, 16:05 ET TransMedics Reports First Quarter 2026 Financial Results
ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported
More news about: TransMedics Group, Inc.
Apr 29, 2026, 09:26 ET TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
ANDOVER, Mass., April 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced
More news about: TransMedics Group, Inc.
Apr 29, 2026, 09:00 ET The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
in that conversation: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Senseonics (NASDAQ: SENS), TransMedics Group (NASDAQ: TMDX), WELL Health Technologies (TSX: WELL) (OTCQX: WHTCF), and 10x Genomics (NASDAQ: TXG).
More news about: Equity Insider
Apr 23, 2026, 07:00 ET TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
ANDOVER, Mass., April 23, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, is today providing
More news about: TransMedics Group, Inc.
Apr 21, 2026, 16:05 ET TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced
More news about: TransMedics Group, Inc.
Feb 27, 2026, 07:00 ET TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued
More news about: TransMedics Group, Inc.
Feb 24, 2026, 16:05 ET TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported
More news about: TransMedics Group, Inc.